Fig. 5: Changes of metabolite levels in relation to APC and CEG signature activity.
Shown are the relative intensities in % as box and whisker plots (box spans interquartile range (IQR), centerline indicates median, whisker extend 1.5 IQR from first and third quartile, observations beyond shown as individual points grouped by signature activity of metabolites detected either by MSI (spatial, patients n = 8, samples n = 32, spots by class APC high, not significant, low n = 2486, 16,565, 731, CEG high, not significant, low n = 603, 18,984, 195) or HRMAS NMR (bulk, patients n = 37, samples n = 174, by class APC high, not significant, low n = 35, 114, 25, CEG high, not significant, low n = 19, 136, 19) placed according to their position in the indicated simplified metabolic pathways (glycolysis, TCA cycle, uric acid cycle). Metabolite level changes (up or down) in spots (spatial) or samples (bulk) with an increased signature activity compared to low signature activity are indicated with up or down arrows (blue = APC, magenta = CEG signature). One-sided p values obtained using permutation test (n = 1000) were used to assign significant high/low ST spots (p value ≤0.05/number of signature genes [pAPC ≤0.001, pCEG ≤0.003], absolute score >200, no further multiple testing adjustment) and bulk samples (p value ≤0.05, absolute score >200, no multiple testing adjustment). Exact p values for each spot/sample provided in source data tables for Supplementary Fig. 3 (ST), 10, and 11 (bulk).
